Leukemias are subdivided into acute or chronic types, and then further subdivided into what type of blood cell they start from, lymphocytic (usually from white blood cells that fight infection) or myelogenous (cells in the bone marrow that eventually produce red blood cells).
Meet the moon shot leaders poised to make dramatic advances in the treatment of chronic lymphocytic leukemia (CLL), the most common type of leukemia in the U.S. and Europe, mostly affecting people over 55. Our goals are to replace traditional chemotherapy drugs as the front-line treatment of CLL, improve the one-year survival rate, increase the number of patients who are disease-free after 10 years, and discover new treatments that minimize toxic effects of standard chemotherapy. #endcancer
More than 250,000 people are living with, or in remission from, leukemia in the United States today. Treatments for leukemia have come a long way since the early 1900s when the primary therapy for the disease was arsenic.